Trial Profile
A Phase 1 Study of CC-11050 in Human Immunodeficiency Virus-1-Infected Adults With Suppressed Plasma Viremia on Antiretroviral Therapy
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Dovramilast (Primary)
- Indications HIV-1 infections
- Focus Adverse reactions
- Acronyms APHRODITE
- 27 Jul 2018 Results assessing the safety of CC-11050 in HIV+ people with suppressed viral load on antiretroviral therapy presented at the 22nd International AIDS Conference
- 16 May 2017 Status changed from recruiting to completed.
- 17 Dec 2016 Planned End Date changed from 1 Oct 2017 to 1 Dec 2017.